文献速递白血病造血干细胞移植与细胞治疗

青少年和年轻成人急性淋巴细胞白血病:儿科方案与造血干细胞移植的系统评价

Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

该系统评价比较了青少年和年轻成人(15-39岁)急性淋巴细胞白血病(ALL)中天冬酰胺酶为基础的儿科方案与非天冬酰胺酶为基础的成人方案,以及异基因造血干细胞移植与不移植的疗效。Meta分析显示儿科方案与更高的5年总生存、无事件生存和无病生存相关,且治疗相关死亡率更低;移植与更低的5年总生存和无病生存以及更高的非复发死亡相关。证据质量低,缺乏随机对照试验。

要点

  • 儿科方案可能改善费城染色体阴性ALL患者的生存。
  • 异基因造血干细胞移植可能降低总生存和无病生存。
  • 证据总体质量低,需高质量研究验证。

核心结论

  • 在青少年和年轻成人ALL中,儿科方案与更好的生存相关,而造血干细胞移植与更差的生存相关,但证据确定性低。

主要发现

  • 儿科方案 vs 成人方案:5年总生存RR 1.40(95%CI 1.18-1.65),无事件生存RR 1.80(95%CI 1.13-2.85),无病生存RR 1.55(95%CI 1.32-1.82),治疗相关死亡率RR 0.29(95%CI 0.09-0.90)。
  • 移植 vs 不移植:5年总生存RR 0.72(95%CI 0.61-0.84),无病生存RR 0.78(95%CI 0.68-0.90),非复发死亡率RR 2.70(95%CI 1.18-6.18),治疗相关死亡率HR 6.88(95%CI 3.02-15.70)。
  • 复发风险随时间点变化。

关键数值与推荐

  • 儿科方案与更高的5年OS、EFS、DFS和更低的TRM相关;HSCT与更低的5年OS、DFS和更高的NRM、TRM相关。
  • 在费城染色体阴性ALL的AYAs中,儿科方案可能改善生存;毒性相关证据有限。

临床怎么用

  • 对于AYAs ALL,可考虑优先选择儿科方案;HSCT可能带来生存劣势,需谨慎选择。

局限性

  • 研究多为低质量,随机对照试验稀少,证据确定性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The best frontline treatment for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs) is unclear. To support a clinical practice guideline, we systematically reviewed and meta-analyzed evidence on (1) asparaginase-based (pediatric) vs non-asparaginase-based (adult) regimens and (2) allogeneic hematopoietic stem cell transplantation (HSCT) vs no HSCT for AYAs (aged 15-39 years) with ALL in first complete remission. Data sources were PubMed, CINAHL, and PsycINFO from inception to 29 November 2023. Eligible studies compared regimens or the use of HSCT and reported survival, remission, toxicity, or quality of life in AYAs. We included 19 studies (14 comparative, 5 single-group; N = 3607) comparing regimens and 7 studies (N = 7492) comparing HSCT and no HSCT. Studies were mostly of poor quality, with sparse randomized controlled trials (RCTs), yielding low-certainty findings. Pediatric regimens were associated with higher 5-year overall survival (OS; relative risk [RR], 1.40; 95% confidence interval [CI], 1.18-1.65), event-free survival (RR, 1.80; 95% CI, 1.13-2.85), disease-free survival (DFS; RR, 1.55; 95% CI, 1.32-1.82), and lower treatment-related mortality (TRM; RR, 0.29; 95% CI, 0.09-0.90). HSCT was associated with lower 5-year OS (RR, 0.72; 95% CI, 0.61-0.84) and DFS (RR, 0.78; 95% CI, 0.68-0.90) and higher nonrelapse mortality (RR, 2.70; 95% CI, 1.18-6.18) and TRM (hazard ratio, 6.88; 95% CI, 3.02-15.70). Relapse risk varied by time point. In AYAs with Philadelphia chromosome-negative ALL, pediatric regimens may improve survival; toxicity-related evidence remains limited. HSCT may lead to inferior OS and DFS. With a dearth of RCTs, low-certainty evidence highlights the need for high-quality studies and subanalyses of AYAs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sereda Y, Mai HJ, Kanaan G, et al. Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia. Blood Adv. 2026. PMID: 41610329. doi:10.1182/bloodadvances.2025018736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。